Enzymatica AB: Excellent volume growth for ColdZyme®
Q2 · Net sales reached SEK 4.9 (3.1) million. · Loss after tax came in at SEK -12.3 (-10.4) thousand. · Earnings per share were SEK -0.20 (-0.42). · Cash and cash equivalents were SEK 26.9 (23.4) thousand Significant events in Q2 · Enzymatica completed its acquisition of Icelandic company Zymetech effective April 1. · Enzymatica completed its new share issue, raising SEK 60 million before issue expenses. H1 · Net sales increased to SEK 13.3 (10.0) million. · Loss after tax came in at SEK -20.9 (-19.5) million. ·